Online inquiry

IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4816MR)

This product GTTS-WQ4816MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD4 gene. The antibody can be applied in Psoriasis, Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000616.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 920
UniProt ID P01730
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4816MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8306MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ3582MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ14680MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ12495MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ623MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ1245MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ6088MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ3591MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1129980
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW